echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Darui Bio Announces Exclusive Licensing Deal with Sanofi for Small Nucleic Acid Pipeline and Technology Platform

    Darui Bio Announces Exclusive Licensing Deal with Sanofi for Small Nucleic Acid Pipeline and Technology Platform

    • Last Update: 2022-08-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Darui Biomedical Technology (Shanghai) .


    Under the agreement, Darui also acquired rights to further develop, manufacture and commercialize drug candidates based on four preclinical liver-targeted progra.


    Under the terms of the agreement, Darui will pay Sanofi an upfront payment and further royalties based on R&D and commercial milestones and net product sal.


    If this article violates your rights, please contact .


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.